Artisan Partners Limited Partnership Sells 28,849 Shares of Humana Inc. $HUM

Artisan Partners Limited Partnership lessened its holdings in Humana Inc. (NYSE:HUM) by 3.9% in the third quarter, Holdings Channel reports. The firm owned 702,637 shares of the insurance provider’s stock after selling 28,849 shares during the period. Artisan Partners Limited Partnership’s holdings in Humana were worth $182,805,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the business. Elevation Point Wealth Partners LLC bought a new position in Humana during the second quarter valued at about $32,000. Mather Group LLC. purchased a new position in Humana in the third quarter valued at about $34,000. Private Wealth Management Group LLC boosted its stake in Humana by 47.5% in the third quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock valued at $39,000 after acquiring an additional 48 shares during the last quarter. AlphaCore Capital LLC bought a new position in shares of Humana during the 2nd quarter valued at approximately $39,000. Finally, SJS Investment Consulting Inc. increased its stake in shares of Humana by 19,300.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 194 shares of the insurance provider’s stock worth $50,000 after purchasing an additional 193 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Raymond James Financial reduced their price objective on Humana from $340.00 to $230.00 and set an “outperform” rating for the company in a report on Friday, February 13th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $344.00 price target on shares of Humana in a research report on Tuesday, January 6th. TD Cowen decreased their price objective on Humana from $260.00 to $173.00 and set a “hold” rating for the company in a report on Friday, February 13th. Oppenheimer set a $250.00 price objective on Humana in a research note on Thursday, February 12th. Finally, Wolfe Research increased their target price on shares of Humana from $300.00 to $325.00 and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Seven investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $225.48.

Humana Stock Up 6.1%

HUM opened at $186.88 on Friday. The firm has a market capitalization of $22.54 billion, a P/E ratio of 19.03, a price-to-earnings-growth ratio of 1.88 and a beta of 0.44. Humana Inc. has a one year low of $169.61 and a one year high of $315.35. The company has a fifty day moving average price of $230.72 and a 200-day moving average price of $256.54. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.00.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The company had revenue of $32.64 billion during the quarter, compared to analyst estimates of $32.08 billion. During the same quarter last year, the company earned ($2.16) earnings per share. The firm’s quarterly revenue was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Equities research analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Friday, March 27th. Humana’s dividend payout ratio is 36.05%.

Insiders Place Their Bets

In related news, insider Sanjay K. Shetty purchased 810 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was acquired at an average price of $185.21 per share, with a total value of $150,020.10. Following the purchase, the insider directly owned 11,657 shares in the company, valued at approximately $2,158,992.97. This represents a 7.47% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.37% of the stock is owned by corporate insiders.

Key Stories Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Insider buying: Humana insider Sanjay Shetty purchased 810 shares at about $185.21, increasing his stake ~7.5% — a classic signal of insider confidence that can support near‑term sentiment. Insider Buying
• Positive Sentiment: CenterWell expansion: Humana’s CenterWell acquired a Florida primary-care network, expanding its direct-care footprint and supporting longer‑term membership and care‑coordination strategies that investors reward. Acquisition Article
• Positive Sentiment: Dividend + institutional inflows: The company declared a quarterly dividend (annualized ~$3.54, ~2.0% yield) and filings show large institutional buying from groups like Capital International, MFS and Norges Bank — both items support demand for the stock. MarketBeat Humana
• Neutral Sentiment: Investor presentation scheduled: CEO Jim Rechtin and CFO Celeste Mellet will present at the Leerink Partners Global Healthcare Conference on March 10; management commentary could move the shares depending on tone and new disclosures. Conference Notice
• Neutral Sentiment: Local operations/profile piece: A regional profile on Humana Group Benefits in San Antonio highlights relationship-driven growth but is unlikely to move the stock materially. Local Profile
• Negative Sentiment: Analyst downgrades and cuts: Barclays cut its price target to $176 and kept an equal‑weight rating; other shops (Zacks, Leerink, Weiss) have issued cautious or negative notes — analyst tone is pressuring sentiment and caps upside. Barclays PT Cut
• Negative Sentiment: Zacks / peer comparison: Zacks’ commentary and comparative pieces argue UnitedHealth (UNH) has better upside given scale versus Humana, and Zacks moved to a more bearish stance — a headwind for investors seeking sector winners. Zacks Comparison

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.